These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32508566)

  • 1. LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson's.
    Wallings RL; Herrick MK; Tansey MG
    Front Neurosci; 2020; 14():443. PubMed ID: 32508566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2 as a target for modulating immune system responses.
    Russo I; Bubacco L; Greggio E
    Neurobiol Dis; 2022 Jul; 169():105724. PubMed ID: 35427743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases.
    Tsafaras G; Baekelandt V
    Neurobiol Dis; 2022 Oct; 172():105806. PubMed ID: 35781002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 regulation of immune-pathways and inflammatory disease.
    Wallings RL; Tansey MG
    Biochem Soc Trans; 2019 Dec; 47(6):1581-1595. PubMed ID: 31769472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo.
    Kozina E; Sadasivan S; Jiao Y; Dou Y; Ma Z; Tan H; Kodali K; Shaw T; Peng J; Smeyne RJ
    Brain; 2018 Jun; 141(6):1753-1769. PubMed ID: 29800472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple-Hit Hypothesis in Parkinson's Disease: LRRK2 and Inflammation.
    Cabezudo D; Baekelandt V; Lobbestael E
    Front Neurosci; 2020; 14():376. PubMed ID: 32410948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to
    Weindel CG; Bell SL; Vail KJ; West KO; Patrick KL; Watson RO
    Elife; 2020 Feb; 9():. PubMed ID: 32057291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leucine Rich Repeat Kinase 2 and Innate Immunity.
    Ahmadi Rastegar D; Dzamko N
    Front Neurosci; 2020; 14():193. PubMed ID: 32210756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant LRRK2 exacerbates immune response and neurodegeneration in a chronic model of experimental colitis.
    Cabezudo D; Tsafaras G; Van Acker E; Van den Haute C; Baekelandt V
    Acta Neuropathol; 2023 Aug; 146(2):245-261. PubMed ID: 37289222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease.
    Lee H; James WS; Cowley SA
    Biochem Soc Trans; 2017 Feb; 45(1):131-139. PubMed ID: 28202666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders.
    Puccini JM; Marker DF; Fitzgerald T; Barbieri J; Kim CS; Miller-Rhodes P; Lu SM; Dewhurst S; Gelbard HA
    J Neurosci; 2015 Apr; 35(13):5271-83. PubMed ID: 25834052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is LRRK2 the missing link between inflammatory bowel disease and Parkinson's disease?
    Herrick MK; Tansey MG
    NPJ Parkinsons Dis; 2021 Mar; 7(1):26. PubMed ID: 33750819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond.
    Bae JR; Lee BD
    BMB Rep; 2015 May; 48(5):243-8. PubMed ID: 25703537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2 G2019S and Parkinson's disease: insight from Neuroinflammation.
    Yao XY; Guan LN; Chen Q; Ren C
    Postgrad Med J; 2023 Dec; 100(1179):4-11. PubMed ID: 37777187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2; Communicative Role in the Treatment of Parkinson's Disease and Ulcerative Colitis Overlapping.
    Lashgari NA; Roudsari NM; Niknejad A; Shamsnia HS; Shayan M; Shalmani LM; Momtaz S; Rezaei N; Abdolghaffari AH
    CNS Neurol Disord Drug Targets; 2024; 23(10):1177-1188. PubMed ID: 38279762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.
    Lee BD; Dawson VL; Dawson TM
    Trends Pharmacol Sci; 2012 Jul; 33(7):365-73. PubMed ID: 22578536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 in Transcription and Translation Regulation: Relevance for Parkinson's Disease.
    Dorval V; Hébert SS
    Front Neurol; 2012; 3():12. PubMed ID: 22363314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 and the Immune System.
    Dzamko NL
    Adv Neurobiol; 2017; 14():123-143. PubMed ID: 28353282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Double-Faceted Role of Leucine-Rich Repeat Kinase 2 in the Immunopathogenesis of Parkinson's Disease.
    Zhang M; Li C; Ren J; Wang H; Yi F; Wu J; Tang Y
    Front Aging Neurosci; 2022; 14():909303. PubMed ID: 35645775
    [No Abstract]   [Full Text] [Related]  

  • 20. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
    Chen J; Chen Y; Pu J
    Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.